This observational study is looking at how LEQEMBI (lecanemab), a treatment for Alzheimer's disease, affects amyloid plaques in the brain and retina. Researchers want to see if there's a connection between amyloid in the retina and a brain side effect called ARIA (Amyloid-Related Imaging Abnormalities), and if LEQEMBI can reduce amyloid in the retina. You might be able to join if you are 50 years or older, have mild cognitive impairment due to Alzheimer's disease, and are eligible for and plan to receive LEQEMBI as part of your regular care. The main goal is to measure changes in retinal blood vessels and their winding pattern over one year. The current recruitment status for this study is unclear.

Study design

This is an observational study with a planned enrollment of 200 participants. It is not specified what phase the study is in.

What's involved

You would need to be willing to follow the study's rules, including having your pupils dilated to at least 3.5 mm for eye imaging.

Compensation

Not stated in the trial record.

Follow-up

Retinal vessel and tortuosity (winding pattern) will be measured from enrollment to the end of treatment at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.